Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023
  • About Us
    • About Senores
    • Milestone
    • Leadership
      • Board of Directors
      • Senior Management
    • Partnership
    • Corporate Film
  • Manufacturing
    • Formulations
    • API
  • Products
    • Formulation – Regulated Market
    • Formulation – Emerging Market
    • API
    • Critical Care – Hospital Line
    • Private Label
  • R&D
  • Investors
    • Announcements
    • Financials
    • Shareholding Pattern
    • Corporate Governance Reports
    • Reports
    • Policies
    • Committees
    • Investor Meet
    • Investor Contacts
    • MOA-AOA
    • Reg. 46 of SEBI (LODR) Regulations
    • Offer Documents
  • Contact

Announcements
FY 2025 - 2026
    • Intimation of Media Release – 05.12.2025
    • Earnings Conference Call Q2 & H1FY26 – Transcript
    • Intimation for Newspaper Publication – 07.11.2025
    • Outcome of Investor Call – 06.11.2025
    • Intimation for Monitoring Agency Report – 06.11.2025
    • Intimation for Change in SMP – 06.11.2025
    • Intimation for Investor Presentation
    • Intimation for Media Release
    • Financial Results for Q2 & H1FY26
    • Outcome of Board Meeting – 06.11.2025
    • Intimation Regarding Acqusition – 05.11.2025
    • Intimation Regarding Updates on USFDA Inspection – 05.11.2025
    • Intimation for Earnings Conference Call – 29.10.2025
    • Intimation for Board Meeting – 29.10.2025
    • Intimation regarding change in E-mail Address of RTA – 08.10.2025
    • Trading Window Closure – 26.09.2025
    • Scrutinizer Report and Voting Results for 08th AGM
    • Proceedings of 08th AGM
    • Intimation for Investment in WOS – 18.09.2025
    • Updates on Acquisition of Shares of Havix – 12.09.2025
    • Intimation for Corrigendum to the Annual Report – 05.09.2025
    • Intimation for Re-scheduling of Investor Meeting – 02.09.2025
    • Intimation for Newspaper Publication – 28.08.2025
    • Intimation for Investor Meeting – 28.08.2025
    • Notice of Eighth (8th) AGM
    • Intimation for cancellation of Participation in Meet – 19.08.2025
    • Intimation for Investor Meeting – 13.08.2025
    • Media Release – 12.08.2025
    • Intimation for Investor Meeting – 05.08.2025
    • Intimation Transcript of Earnings Call – 30.07.2025
    • Intimation for Completion of USFDA Inspection at Havix
    • Outcome of Earnings Call – 24.07.2025
    • Intimation for Newspaper Publication – 24.07.2025
    • Intimation for Investor Presentation – 23.07.2025
    • Intimation for Monitoring Agency Report – 23.07.2025
    • Intimation for Media Release – 23.07.2025
    • Financial Results for Q1 FY2025-26 – 23.07.2025
    • Intimation for change in SMP – 23.07.2025
    • Outcome of Board Meeting – 23.07.2025
    • Intimation for Earnings Conference Call – 19.07.2025
    • Intimation of Board Meeting – 17.07.2025
    • Intimation for Corporate Guarantee – 10.07.2025
    • Intimation for Share acquisition of Havix – 10.07.205
    • Trading Window Closure – 25.06.2025
    • Updates on Acquisition of Shares of Havix – 23.06.2025
    • Intimation for Investor Meeting – 18.06.2025
    • Outcome of Board Meeting – 02.06.2025
    • Intimation for appointment of Internal Auditors – 02.06.2025
    • Intimation for Transcript of Earnings Conference Call-22.05.2025
    • Media Release – 20.05.2025
    • Intimation regarding Outcome of Earnings Conference Call – 16.05.2025
    • Intimation for Newspaper Publication – 16.05.2025
    • Intimation for Investor Presentation – 16.05.2025
    • Intimation for Monitoring Agency Report – 15.05.2025
    • Intimation for Changes in Senior Managerial Personnel – 15.05.2025
    • Intimation for Appointmnet of Secretarial Auditor – 15.05.2025
    • Intimation of Media Release – 15.05.2025
    • Outcome of Board Meeting – 15.05.2025
    • Intimation for Earnings Call – 12.05.2025
    • Intimation of Board Meeting – 09.05.2025
    • Media Release – 09.05.2025
    • Media Release – 05.05.2025
    • Intimation under Regulation 30 – 02.05.2025
    • Updates on Acquisition of Shares of Havix – 22.04.2025
    • Intimation regarding change in contact details of RTA – 19.04.2025
    • Intimation for Update in MCA Master Data – 04.04.2025
    • Intimation for Investor Meeting – 03.04.2025
    • Intimation for Corporate Guarantee – 02.04.2025
FY 2024 - 2025
  • Trading Window Closure – 27.03.2025
  • Intimation for investment in WOS – 20.03.2025
  • Additional Disclosure regarding Acquisition – Havix – 12.03.2025
  • Intimation for share acquisition of Havix – 11.03.2025
  • Intimation for Investor Meet – 06.03.2025
  • Media Release – 04.03.2025
  • Media Release – 26.02.2025
  • Media Release – 20.02.2025
  • Intimation regarding change of domain name of RTA – 18.02.2025
  • Intimation for Investor Meet – 06.02.2025 & 07.02.2025
  • Intimation for Transcript of Earnings Conference Call
  • Intimation for Newspaper Publication – 24.01.2025
  • Intimation regarding Outcome of Earnings Conference Call – 23.01.2025
  • Integrated Filing – Financials – 23.01.2025
  • Intimation for Monitoring Agency Report – 23.01.2025
  • Intimation for Appointment of Secretarial Auditor – 23.01.2025
  • Intimation for Investor Presentation – 23.01.2025
  • Statement of Deviation and Variation – 23.01.2025
  • Outcome of Board Meeting – 23.01.2025
  • Intimation of Media Release – 23.01.2025
  • Intimation for Investment in Subsidiary – 20.01.2025
  • Intimation for Earnings Call
  • Intimation of Board Meeting – 10.01.2025
  • Media Release – 09.01.2025
  • Trading Window Closure – 31.12.2024
  • KMPs Authorised to Determine Materiality

Useful Links

  • About Us
  • Manufacturing
  • Products
  • Partnership
  • R&D
  • Regulatory
  • Adverse Drug Reaction Reporting Form
  • Media
  • Career
  • Contact

Disclaimer

• All the information present on Senores Pharmaceuticals website is not applicable to all the countries across the world. The  purpose  of   this  website is to provide information about Senores Pharmaceuticals' products and services. Any information present on the website shouldn't be misused or construed to spread or promote any of the products in the countries where are disapproved or prohibited.
• Listed  products  in this website will not be supplied to countries in which these could be in conflict with existing valid patents. The buyers should make their independent evaluation of the patent scenario for their respective market as the final responsibility lies exclusively with the buyer.
• Patented products will only be supplied for development, testing, and regulatory submission purposes.

© 2023 Senores Pharmaceuticals | All Rights Reserved.